AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland.
<h4>Background</h4>Narcolepsy is a chronic sleep disorder with strong genetic predisposition causing excessive daytime sleepiness and cataplexy. A sudden increase in childhood narcolepsy was observed in Finland soon after pandemic influenza epidemic and vaccination with ASO3-adjuvanted P...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4a4918ef34e0423fbb98c46b23a6d067 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4a4918ef34e0423fbb98c46b23a6d067 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4a4918ef34e0423fbb98c46b23a6d0672021-11-18T07:24:05ZAS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland.1932-620310.1371/journal.pone.0033536https://doaj.org/article/4a4918ef34e0423fbb98c46b23a6d0672012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22470453/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Narcolepsy is a chronic sleep disorder with strong genetic predisposition causing excessive daytime sleepiness and cataplexy. A sudden increase in childhood narcolepsy was observed in Finland soon after pandemic influenza epidemic and vaccination with ASO3-adjuvanted Pandemrix. No increase was observed in other age groups.<h4>Methods</h4>Retrospective cohort study. From January 1, 2009 to December 31, 2010 we retrospectively followed the cohort of all children living in Finland and born from January 1991 through December 2005. Vaccination data of the whole population was obtained from primary health care databases. All new cases with assigned ICD-10 code of narcolepsy were identified and the medical records reviewed by two experts to classify the diagnosis of narcolepsy according to the Brighton collaboration criteria. Onset of narcolepsy was defined as the first documented contact to health care because of excessive daytime sleepiness. The primary follow-up period was restricted to August 15, 2010, the day before media attention on post-vaccination narcolepsy started.<h4>Findings</h4>Vaccination coverage in the cohort was 75%. Of the 67 confirmed cases of narcolepsy, 46 vaccinated and 7 unvaccinated were included in the primary analysis. The incidence of narcolepsy was 9.0 in the vaccinated as compared to 0.7/100,000 person years in the unvaccinated individuals, the rate ratio being 12.7 (95% confidence interval 6.1-30.8). The vaccine-attributable risk of developing narcolepsy was 1:16,000 vaccinated 4 to 19-year-olds (95% confidence interval 1:13,000-1:21,000).<h4>Conclusions</h4>Pandemrix vaccine contributed to the onset of narcolepsy among those 4 to 19 years old during the pandemic influenza in 2009-2010 in Finland. Further studies are needed to determine whether this observation exists in other populations and to elucidate potential underlying immunological mechanism. The role of the adjuvant in particular warrants further research before drawing conclusions about the use of adjuvanted pandemic vaccines in the future.Hanna NohynekJukka JokinenMarkku PartinenOuti VaaralaTurkka KirjavainenJonas SundmanSari-Leena HimanenChrister HublinIlkka JulkunenPäivi OlsénOuti Saarenpää-HeikkiläTerhi KilpiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 3, p e33536 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Hanna Nohynek Jukka Jokinen Markku Partinen Outi Vaarala Turkka Kirjavainen Jonas Sundman Sari-Leena Himanen Christer Hublin Ilkka Julkunen Päivi Olsén Outi Saarenpää-Heikkilä Terhi Kilpi AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. |
| description |
<h4>Background</h4>Narcolepsy is a chronic sleep disorder with strong genetic predisposition causing excessive daytime sleepiness and cataplexy. A sudden increase in childhood narcolepsy was observed in Finland soon after pandemic influenza epidemic and vaccination with ASO3-adjuvanted Pandemrix. No increase was observed in other age groups.<h4>Methods</h4>Retrospective cohort study. From January 1, 2009 to December 31, 2010 we retrospectively followed the cohort of all children living in Finland and born from January 1991 through December 2005. Vaccination data of the whole population was obtained from primary health care databases. All new cases with assigned ICD-10 code of narcolepsy were identified and the medical records reviewed by two experts to classify the diagnosis of narcolepsy according to the Brighton collaboration criteria. Onset of narcolepsy was defined as the first documented contact to health care because of excessive daytime sleepiness. The primary follow-up period was restricted to August 15, 2010, the day before media attention on post-vaccination narcolepsy started.<h4>Findings</h4>Vaccination coverage in the cohort was 75%. Of the 67 confirmed cases of narcolepsy, 46 vaccinated and 7 unvaccinated were included in the primary analysis. The incidence of narcolepsy was 9.0 in the vaccinated as compared to 0.7/100,000 person years in the unvaccinated individuals, the rate ratio being 12.7 (95% confidence interval 6.1-30.8). The vaccine-attributable risk of developing narcolepsy was 1:16,000 vaccinated 4 to 19-year-olds (95% confidence interval 1:13,000-1:21,000).<h4>Conclusions</h4>Pandemrix vaccine contributed to the onset of narcolepsy among those 4 to 19 years old during the pandemic influenza in 2009-2010 in Finland. Further studies are needed to determine whether this observation exists in other populations and to elucidate potential underlying immunological mechanism. The role of the adjuvant in particular warrants further research before drawing conclusions about the use of adjuvanted pandemic vaccines in the future. |
| format |
article |
| author |
Hanna Nohynek Jukka Jokinen Markku Partinen Outi Vaarala Turkka Kirjavainen Jonas Sundman Sari-Leena Himanen Christer Hublin Ilkka Julkunen Päivi Olsén Outi Saarenpää-Heikkilä Terhi Kilpi |
| author_facet |
Hanna Nohynek Jukka Jokinen Markku Partinen Outi Vaarala Turkka Kirjavainen Jonas Sundman Sari-Leena Himanen Christer Hublin Ilkka Julkunen Päivi Olsén Outi Saarenpää-Heikkilä Terhi Kilpi |
| author_sort |
Hanna Nohynek |
| title |
AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. |
| title_short |
AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. |
| title_full |
AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. |
| title_fullStr |
AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. |
| title_full_unstemmed |
AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. |
| title_sort |
as03 adjuvanted ah1n1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in finland. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/4a4918ef34e0423fbb98c46b23a6d067 |
| work_keys_str_mv |
AT hannanohynek as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland AT jukkajokinen as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland AT markkupartinen as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland AT outivaarala as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland AT turkkakirjavainen as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland AT jonassundman as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland AT sarileenahimanen as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland AT christerhublin as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland AT ilkkajulkunen as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland AT paiviolsen as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland AT outisaarenpaaheikkila as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland AT terhikilpi as03adjuvantedah1n1vaccineassociatedwithanabruptincreaseintheincidenceofchildhoodnarcolepsyinfinland |
| _version_ |
1718423531254972416 |